Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C8 | P10632 | 1/20 | 0.38 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.37 |
| ▸ | MCHR1 | Q99705 | 5/20 | 0.35 |
| ▸ | PPARG | P37231 | 5/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.34 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.33 |
| ▸ | AURKA | O14965 | 1/20 | 0.33 |
| ▸ | TPX2 | Q9ULW0 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL831956 | 0.90 | CYP2C8 (0.40) | CYP2C8PPARGKMT2APTGER4OPRL1 | |
| SCHEMBL831751 | 0.88 | CYP2C8 (0.41) | CYP2C8PTGDR2KMT2APTGER4MEN1 | |
| SCHEMBL832336 | 0.88 | CYP2C8 (0.39) | CYP2C8PTGDR2PPARGKMT2AMEN1 | |
| SCHEMBL832179 | 0.87 | CYP2C8 (0.49) | CYP2C8KMT2APTGER4MEN1AURKA | |
| SCHEMBL832356 | 0.87 | CYP2C8 (0.40) | CYP2C8KMT2APTGER4AURKATPX2 | |
| SCHEMBL831547 | 0.86 | CYP2C8 (0.56) | CYP2C8KMT2APTGER4MEN1AURKA | |
| SCHEMBL831907 | 0.85 | SCN9A (0.34) | CYP2C8PTGER4AURKATPX2 | |
| SCHEMBL862404 | 0.85 | CYP2C8 (0.40) | CYP2C8PPARGKMT2APTGER4MEN1 | |
| SCHEMBL831963 | 0.85 | CYP2C8 (0.40) | CYP2C8PTGDR2KMT2AMEN1 | |
| SCHEMBL831683 | 0.85 | CYP2C8 (0.38) | CYP2C8PTGDR2PPARGKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8143305-B2 | 2,3-substituted indole derivatives for treating viral infections | SCHERING CORPORATION (US) | 2012-03-27 | — | — | US | disclosed |
| US-8143305-B2 | 2,3-substituted indole derivatives for treating viral infections | SCHERING CORPORATION (US) | 2012-03-27 | — | — | US | disclosed |
| US-20110033417-A1 | 2,3-SUBSTITUTED INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS | MERCK SHARP & DOHME CORP. | 2011-02-10 | — | — | US | disclosed |
| US-20110033417-A1 | 2,3-SUBSTITUTED INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS | MERCK SHARP & DOHME CORP. | 2011-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110033417-A1 | 2,3-SUBSTITUTED INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS | IDO2, IDO1, IRF3 | CYP2C8 847/4885PTGDR2 1609/4885MCHR1 955/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.